PTAFR and neoplasm: Using a SKOV-3-luciferase xenograft model, the authors also showed that the combined treatment with cisplatin and a PAFR antagonist (ginkgolide B) inhibited tumor progression 56, reinforcing the hypothesis that the PAF/PAFR axis is involved in tumor survival and that its blockade impairs tumor progression.